Needham analyst David Saxon raised the firm’s price target on Glaukos (GKOS) to $127 from $125 and keeps a Buy rating on the shares after its Q4 revenue came in-line with its pre-announcement. iDose continues to ramp, with re-administration potentially starting to drive volume in the second half of this year, which should build into 2027 and beyond, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos (GKOS): Strong Execution, Expanding iDose Adoption, and De‑Risked Pipeline Support Buy Rating and $131 Target
- Glaukos: Strengthening Growth, Epioxa Momentum, and Justified Premium Valuation Support Buy Rating
- Glaukos price target raised to $135 from $122 at Wells Fargo
- Closing Bell Movers: Palo Alto Networks down 8% on soft guidance
- Glaukos Reports Record Q4 Sales, Reaffirms 2026 Outlook